Actavis set to pay US$66 billion for Allergan

17 November 2014 - Deborah Wilkes

Archived

Actavis is set to acquire Allergan in a US$66 billion cash and shares deal that appears to have ended Valeant Pharmaceuticals International's hostile bid for the US-based maker of Botox.

Annual Subscription Holder?

Sign in to continue reading.
 

Sign In

Back to Industry News

Share this page: